Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

The eBEACOPP regimen, consisting of bleomycin, vincristine, procarbazine and prednisone plus escalated doses of etoposide, doxorubicin and cyclophosphamide, is a standard frontline treatment for classical Hodgkin lymphoma (cHL). This intensive regimen confers the highest primary cure rates but also considerable and often persistent treatment-related morbidities.

EBEACOP方案由博来霉素，长春新碱，丙卡巴嗪和泼尼松加上递增剂量的依托泊苷，多柔比星和环磷酰胺组成，是经典霍奇金淋巴瘤（cHL）的标准一线治疗方法。这种强化治疗方案具有最高的一级治愈率，但也存在相当大且通常持续的治疗相关疾病。

Now, data from the HD21 trial demonstrate the improved risk-to-benefit ratio of a new regimen comprising the antibody–drug conjugate brentuximab vedotin plus etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD).In this phase III trial, 1,500 patients of 18–60 years of age with advanced-stage cHL were randomly assigned (1:1) to receive PET-guided treatment with BrECADD versus eBEACOPP, each for 4 cycles if PET-2 negative (Deauville score 1–3 after cycle 2) or 6 cycles if PET-2 positive (Deauville score 4–5).

现在，来自HD21试验的数据表明，包含抗体-药物偶联物brentuximab vedotin加依托泊苷，环磷酰胺，多柔比星，达卡巴嗪和地塞米松（BrECADD）的新方案的风险效益比有所提高。在这项III期试验中，1500名18-60岁的晚期cHL患者被随机分配（1:1）接受BrECADD与EBEACOP的PET指导治疗，如果PET-2阴性（第2周期后多维尔评分1-3），则每个周期4个周期，如果PET-2阳性（多维尔评分4-5），则每个周期6个周期。

The co-primary end points were improved tolerability, defined by investigator-assessed treatment-related morbidity (acute grade 4 haematological or grade 3–4 non-haematological organ system toxicities), and non-inferior progression-free survival (PFS)..

共同主要终点是改善耐受性，由研究者评估的治疗相关发病率（急性4级血液学或3-4级非血液学器官系统毒性）和非劣效无进展生存期（PFS）定义。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springer link上购买即时访问完整文章PDFBuy now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesOriginal articleBorchmann, P. et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(24)01315-1 (2024)Article .

参考文献Original articleBorchmann，P。等人评估PET引导的BrECADD与EBEACOP在晚期经典霍奇金淋巴瘤（HD21）中的疗效和耐受性：一项随机，多中心，平行，开放标签的3期临床试验。柳叶刀https://doi.org/10.1016/S0140-6736（24）01315-1（2024）条。

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsNature Reviews Clinical Oncology http://www.nature.com/nrclinoncDavid KillockAuthorsDavid KillockView author publicationsYou can also search for this author in

下载参考文献作者信息作者和附属机构临床肿瘤学评论http://www.nature.com/nrclinoncDavidKillockAuthorsDavidKillockView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

David Killock.Rights and permissionsReprints and permissionsAbout this articleCite this articleKillock, D. BrECADD raises the bar in classical Hodgkin lymphoma.

大卫·基洛克。权利和许可打印和许可本文引用本文Killock，D。BrECADD提高了经典霍奇金淋巴瘤的标准。

Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00928-5Download citationPublished: 22 July 2024DOI: https://doi.org/10.1038/s41571-024-00928-5Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Clin Oncol（2024）。https://doi.org/10.1038/s41571-024-00928-5Download引文发布日期：2024年7月22日OI：https://doi.org/10.1038/s41571-024-00928-5Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供